- Home
- RENB vs ELTX Comparison
RENB vs ELTX Comparison
Compare RENB & ELTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RENB
- ELTX
- Stock Information
- Founded
- RENB 2011
- ELTX 2011
- Country
- RENB United States
- ELTX United States
- Employees
- RENB N/A
- ELTX N/A
- Industry
- RENB Biotechnology: Pharmaceutical Preparations
- ELTX Biotechnology: Pharmaceutical Preparations
- Sector
- RENB Health Care
- ELTX Health Care
- Exchange
- RENB Nasdaq
- ELTX Nasdaq
- Market Cap
- RENB 121.3M
- ELTX 121.7M
- IPO Year
- RENB N/A
- ELTX N/A
- Fundamental
- Price
- RENB $0.54
- ELTX $6.30
- Analyst Decision
- RENB
- ELTX Strong Buy
- Analyst Count
- RENB 0
- ELTX 3
- Target Price
- RENB N/A
- ELTX $9.50
- AVG Volume (30 Days)
- RENB 552.0K
- ELTX 36.3K
- Earning Date
- RENB 05-14-2025
- ELTX 03-31-2025
- Dividend Yield
- RENB N/A
- ELTX N/A
- EPS Growth
- RENB N/A
- ELTX N/A
- EPS
- RENB N/A
- ELTX N/A
- Revenue
- RENB N/A
- ELTX N/A
- Revenue This Year
- RENB N/A
- ELTX N/A
- Revenue Next Year
- RENB N/A
- ELTX N/A
- P/E Ratio
- RENB N/A
- ELTX N/A
- Revenue Growth
- RENB N/A
- ELTX N/A
- 52 Week Low
- RENB $0.40
- ELTX $3.34
- 52 Week High
- RENB $3.05
- ELTX $11.45
- Technical
- Relative Strength Index (RSI)
- RENB 31.60
- ELTX 31.74
- Support Level
- RENB $0.63
- ELTX $7.54
- Resistance Level
- RENB $0.73
- ELTX $8.13
- Average True Range (ATR)
- RENB 0.07
- ELTX 0.46
- MACD
- RENB -0.02
- ELTX -0.13
- Stochastic Oscillator
- RENB 0.00
- ELTX 1.61
About RENB Renovaro Biosciences Inc.
Renovaro Inc is a biopharmaceutical company. It is engaged in developing new immunotherapies to combat cancer and developing a predicative artificial intelligence-based diagnostic methodology for the use of earlier cancer detection.
About ELTX Elicio Therapeutics Inc.
Elicio Therapeutics Inc is a clinical-stage biotechnology company pioneering the development of cancer immunotherapies for patients with limited treatment options and poor outcomes. Its proprietary Amphiphile, or AMP, platform delivers investigational immunotherapeutics directly to the brain center of the immune system the lymph nodes. Its focus is the development of cancer immunotherapies against biologically validated but hard-to-drug targets that can be activated through lymph node trafficking. Elicio is engineering lymph node-targeted AMPlifiers, immunomodulators, adjuvants, and vaccines for an array of aggressive cancers. It has developed its cancer vaccine product candidates to target biologically validated tumor mutation drivers using known neoantigens.